Cart
sales@molnova.com
RIP2 Kinase Inhibitor 3
CAS No. 1398053-50-3
RIP2 Kinase Inhibitor 3( —— )
Catalog No. M33104 CAS No. 1398053-50-3
RIP2 Kinase Inhibitor 3 is a potent and selective inhibitor of RIP2, demonstrating an IC50 of 1 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 81 | Get Quote |
|
| 5MG | 129 | Get Quote |
|
| 10MG | 226 | Get Quote |
|
| 25MG | 417 | Get Quote |
|
| 50MG | 550 | Get Quote |
|
| 100MG | 805 | Get Quote |
|
| 500MG | 1611 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRIP2 Kinase Inhibitor 3
-
NoteResearch use only, not for human use.
-
Brief DescriptionRIP2 Kinase Inhibitor 3 is a potent and selective inhibitor of RIP2, demonstrating an IC50 of 1 nM.
-
DescriptionRIP2 Kinase Inhibitor 3 is a highly potent and selective inhibitor of receptor interacting protein-2 (RIP2) Kinase with an IC50 of 1 nM .
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetRIP kinase
-
RecptorRIP kinase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1398053-50-3
-
Formula Weight388.48
-
Molecular FormulaC19H24N4O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (64.35 mM; Ultrasonic )
-
SMILESCOc1cc2nccc(Nc3n[nH]c(C)c3C)c2cc1S(=O)(=O)C(C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Haile PA, et al. Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel. ACS Med Chem Lett. 2018 Sep 26;9(10):1039-1044.?
molnova catalog
related products
-
RIPK2-IN-8
A potent, selective, orally available RIPK2 inhibitor with IC50 of 3 nM.
-
HS-1371
HS-1371 (HS1371) is a novel potent, ATP-competitive receptor-interacting protein kinase-3 (RIP3 or RIPK3 kinase) inhibitor with IC50 of 20.8 nM.
-
GSK-843
GSK-843 (GSK'843) is a selective and potent RIP3 inhibitor with an IC50 value of 8.6 nM for the structural domain of RIP3 kinase.
